ReportWire

Tag: hpv vaccine

  • Merck to end HPV vaccine production in Durham, laying off 154 workers

    [ad_1]

    Merck’s Maurice R. Hilleman Center for Vaccine Manufacturing photographed on Apr. 2, 2021, in Durham, N.C.

    Merck’s Maurice R. Hilleman Center for Vaccine Manufacturing photographed on Apr. 2, 2021, in Durham, N.C.

    ctoth@newsobserver.com

    The pharmaceutical giant Merck will stop producing the HPV, or human papillomavirus, vaccine Gardasil at its north Durham facility, a decision it attributes to lower global demand for its second-best selling drug.

    In a Feb. 24 WARN letter to the North Carolina Department of Commerce and Durham County, Merck said this move will result in 154 layoffs. Separations are expected to begin May 1.

    Merck’s decision comes one year after the New Jersey company unveiled a new $1 billion manufacturing plant on Durham’s Old Oxford Road to make Gardasil and Gardasil 9. This facility added 225,000 square feet of production space to a campus that already produced vaccines against measles, rubella, mumps and chickenpox, among other illnesses.

    In her WARN letter this week, plant manager Amanda Taylor wrote Gardasil production would cease at this site due to “the recent worldwide reduction in demand for this product.” Businesses must file WARN notices to North Carolina officials at least 60 days before conducting certain mass layoffs, including the closing of a site “that affects at least 50 employees during any 30-day period.”

    In its latest annual report, released Tuesday, Merck recorded a significant drop in what remains its No. 2 product: Gardasil. The company sold about 40% less last year compared to 2024, dropping from $8.6 billion in Gardasil revenue to $5.2 billion.

    Merck attributed this decrease to suppressed demand in China and Japan, during an investors call in early February. Its executives noted U.S. sales were up, though “largely due to price.”

    Merck’s long history in Durham

    Merck has been in north Durham since 2004. Last year, the company told The News & Observer it had roughly 1,000 employees in the city. The company has told The N&O its layoffs will only impact HPV vaccine manufacturing operations at the site.

    “We continuously assess our operations and evolving business needs,” Merck’s media relations team wrote in an email.

    Seven years ago, Merck signed incentive deals with North Carolina and local governments to expand its operations in Durham and Wilson County. As of 2022, the company had met or surpassed its incentive requirements by creating 353 jobs and retaining 1,247 positions between these two campuses, state records provided to The N&O show. In 2024, the company estimated its Bull City campus produced 70.7 million doses.

    Merck is the world’s 48th-largest public company, by market capitalization, behind fellow drugmakers Eli Lilly and Roche but ahead of than Amgen and Novo Nordisk. Its top-selling product, by a wide margin, is the cancer treatment Keytruda.

    In July, Merck made one of the last year’s largest health care acquisitions when it spent around $10 billion to buy the British drugmaker Verona Pharma, which has its U.S. headquarters in Raleigh. Verona makes a treatment for chronic obstructive pulmonary disease, or COPD, that the Food and Drug Administration approved in June 2024.

    Related Stories from Raleigh News & Observer

    Brian Gordon

    The News & Observer

    Brian Gordon is the Business & Technology reporter for The News & Observer and The Herald-Sun. He writes about jobs, startups and big tech developments unique to the North Carolina Triangle. Brian previously worked as a senior statewide reporter for the USA Today Network. Please contact him via email, phone, or Signal at 919-861-1238.

    [ad_2]

    Brian Gordon

    Source link

  • Doctors have a new tool to increase cervical cancer screening: HPV self-testing

    [ad_1]

    The American Cancer Society now includes self-testing as a recommendation for HPV tests that screen for cervical cancer.

    The American Cancer Society now includes self-testing as a recommendation for HPV tests that screen for cervical cancer.

    iStockphoto

    Doctors in Tarrant County have a new tool that could increase screening for HPV in patients: self-testing.

    The American Cancer Society recently released guidelines recommending self-testing for HPV, allowing people to collect a sample from their cervix themselves instead of having a doctor or nurse collect it. Experts say self-collection could increase HPV screening rates and help detect cervical cancer earlier.

    “Any way that we can increase screening by lowering the barriers to screening is going to be very important,” said Dr. Andrew Wolf, a UVA Health physician who co-authored the new guidelines. “And one way to do that is have women self test.”

    HPV is the most common sexually-transmitted infection in the U.S., according to the U.S. Centers for Disease Control and Prevention.

    HPV can cause cervical cancers, anal cancers, throat and neck cancers, vaginal cancers, vulvar cancers and penile cancers. About 13,000 people get cervical cancer each year, and 4,000 die, according to the CDC, despite vaccines that prevent most types of HPV and cervical cancer screening.

    “This is not acceptable,” Wolf said. “This is a preventable cancer. We can do better if we follow these guidelines and get our children vaccinated.”

    The HPV vaccine protects against two strains of the virus that cause about 70% of cervical cancers, said Dr. Dustin Manders, gynecologic oncologist with Texas Oncology. That means that even if you’re vaccinated, you still need to get screened, said Manders, who is also on the medical staff at Texas Health Presbyterian Hospital Flower Mound.

    “Just because you get the HPV vaccine doesn’t sort of get you off the hook,” he said. “There are still the other 30% of cervical cancers that come from other HPV strains.”

    Today, most cervical cancer screening is done via either an HPV test or a Pap smear.

    Screening for cervical cancer led to a dramatic drop in cervical cancer rates since the 1950s, said Jane Montealegre, an associate professor of behavioral science at University of Texas MD Anderson Cancer Center, but that progress has stalled.

    Today, there are disparities in who gets screened for cervical cancer. Women living in rural areas, who are uninsured or who otherwise have less access to medical services are less likely to be screened, Montealegre said.

    Self-testing may make cervical cancer screening more palatable for patients who have been through trauma or who feel uncomfortable with a healthcare worker doing the test, experts said.

    The self-test is similar to a COVID test, Montealegre said. In research studies, more than 95% of women report that the test is easy to use and that they’re able to follow the instructions accurately.

    The Food and Drug Administration has approved self-testing only in a healthcare office setting, meaning that patients can’t yet self-test at home. Once self-testing at home becomes available, experts said screening rates could improve dramatically.

    Montealegre conducted a research trial in Houston where some of the participants were mailed an HPV self-collection kit, while others received a phone call that told them to come in and see their provider for an HPV test. There was a 2.5-fold increase in screening when kits were sent to women’s homes, Montealegre said.

    “Home-based self-collection really is what we’re all waiting for,” Montealegre said.

    Related Stories from Fort Worth Star-Telegram

    Ciara McCarthy

    Fort Worth Star-Telegram

    Ciara McCarthy covers health and wellness as part of the Star-Telegram’s Crossroads Lab. She came to Fort Worth after three years in Victoria, Texas, where she worked at the Victoria Advocate. Ciara is focused on equipping people and communities with information they need to make decisions about their lives and well-being. Please reach out with your questions about public health or the health care system. Email cmccarthy@star-telegram.com or call or text 817-203-4391.

    [ad_2]

    Ciara McCarthy

    Source link